News Sentiment

NNNN sentiment intelligence

Anbio Biotechnology Class A Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 9.39 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-26.1% over one week, -39.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Anbio Biotechnology Files Mixed Shelf Registration

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction -26.1% Price reacting lower
Trend fit Trend inactive -39.8% over four weeks
Fair value -62.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 26
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
TipRanks 6
Defense World 6
TradingView 4
simplywall.st 2
MarketBeat 2
MT Newswires 1
Benzinga 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 7
Analyst action 2
Balance sheet 1
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 43
TradingView Direct company coverage

Price to earnings forward of Anbio Biotechnology – NASDAQ:NNNN

This article provides financial information for Anbio Biotechnology (NASDAQ:NNNN), specifically focusing on its forward price-to-earnings ratio. The content, sourced from TradingView, indicates "No trades" and is primarily a placeholder or incomplete financial data page, emphasiz

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 18:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Anbio Biotechnology Class A – FWB:N3B

This article provides a brief financial overview for Anbio Biotechnology Class A (FWB:N3B), focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with all copyrights reserved up to

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 05:10
Source
TradingView
TipRanks Direct company coverage

Anbio Biotechnology Soars After Surprise Media Spotlight

Anbio Biotechnology Class A (NNNN) shares are surging after being featured in a Benzinga article on top healthcare stocks for Q2. This rally is attributed to fresh media exposure, renewed optimism for Anbio's diagnostic portfolio, and a technical rebound, rather than broader sect

Tone
Positive 75/100
Event
Market update
Published
22 Jun 2026 14:40
Source
TipRanks
Stock Titan Direct company coverage

Control shifts as Anbio (NNNN) boosts Class B voting power

Anbio Biotechnology shareholders have approved significant changes to the company's capital structure and governance, including a Share Capital Reduction, an Authorised Share Capital Increase, and a substantial boost in voting rights for Class B shares from 50 to 500 votes per sh

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 10:09
Source
Stock Titan
TradingView Direct company coverage

Free cash flow per share of Anbio Biotechnology Class A – FWB:N3B

The article presents information related to the free cash flow per share for Anbio Biotechnology Class A, traded on the Frankfurt Stock Exchange under the symbol N3B. It appears to be a financial data snippet from TradingView, indicating the period, value, and change in free cash

Tone
Neutral 50/100
Event
Balance sheet
Published
01 May 2026 13:39
Source
TradingView
TipRanks Direct company coverage

Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul

Anbio Biotechnology (NNNN) is holding shareholder meetings on May 15, 2026, to approve significant changes to its capital and governance structure. These proposed changes include a reduction in par value, a substantial increase in authorized share capital to introduce new Class C

Tone
Negative 40/100
Event
Market update
Published
27 Apr 2026 23:09
Source
TipRanks
Stock Titan Direct company coverage

Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer

Anbio Biotechnology (NNNN) has filed an Amendment No. 1 to its Form 20-F annual report for the year ended December 31, 2025. The sole purpose of this amendment is to update the cover page to indicate that the company is a well-known seasoned issuer, as defined in Rule 405 of the

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Apr 2026 09:39
Source
Stock Titan
Defense World Direct company coverage

Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)

This article provides a head-to-head analysis of Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), comparing them across valuation, earnings, insider and institutional ownership, profitability, and analyst recommendations. Anbio Biotechnology shows higher revenue and

Tone
Neutral 50/100
Event
Earnings
Published
09 Mar 2026 07:09
Source
Defense World
Defense World Direct company coverage

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review

This article provides a head-to-head comparison between Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), two manufacturing companies, evaluating them on profitability, earnings, valuation, analyst recommendations, and institutional/insider ownership. Anbio Biotechnol

Tone
Neutral 50/100
Event
Earnings
Published
09 Mar 2026 05:51
Source
Defense World
Defense World Direct company coverage

Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)

This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) based on financial metrics, institutional ownership, analyst recommendations, and profitability. Anbio Biotechnology, a company focused on in vitro diagnostics, demonstrates higher revenue and earn

Tone
Neutral 50/100
Event
Earnings
Published
07 Mar 2026 04:53
Source
Defense World
Defense World Direct company coverage

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head to Head Contrast

This article compares Oncocyte (IMDX) and Anbio Biotechnology (NNNN) based on various financial metrics and analyst recommendations. Anbio Biotechnology demonstrates higher revenue and profitability, leading it to outperform Oncocyte in 6 out of 10 comparison factors. The article

Tone
Neutral 50/100
Event
Analyst action
Published
01 Mar 2026 07:52
Source
Defense World
CoinCodex Direct company coverage

Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026–2030

This article provides a comprehensive stock forecast and price prediction for Anbio Biotechnology Class A Ordinary Shares (NNNN) from 2026 to 2030, and further projections up to 2057. It presents yearly and monthly estimated price ranges, details technical analysis, and includes

Tone
Positive 65/100
Event
Guidance
Published
01 Mar 2026 01:51
Source
CoinCodex
Defense World Direct company coverage

Critical Comparison: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)

This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) across various financial metrics, analyst recommendations, and profitability. Anbio Biotechnology outperforms Oncocyte in six out of ten comparison factors, including revenue and earnings. However,

Tone
Neutral 50/100
Event
Earnings
Published
27 Feb 2026 01:51
Source
Defense World
Defense World Direct company coverage

Comparing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)

This article compares Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX), two manufacturing companies, across various financial metrics, analyst recommendations, and ownership details. While analysts favor Oncocyte due to a higher potential upside, Anbio Biotechnology s

Tone
Positive 58/100
Event
Analyst action
Published
25 Feb 2026 06:53
Source
Defense World
TipRanks Direct company coverage

Anbio Biotechnology Replaces Auditor to Safeguard 2025 Reporting Timeline

Anbio Biotechnology dismissed its auditor, HTL International, LLC, and appointed GGF CPA LTD on February 11, 2026. This change was made to ensure the timely completion of its 2025 Form 20-F financial reporting, with no disagreements cited between Anbio and the former auditor. The

Tone
Neutral 50/100
Event
Market update
Published
17 Feb 2026 22:57
Source
TipRanks
Investing.com Direct company coverage

Anbio Biotechnology Stock Price Today | NASDAQ: NNNN Live

This article provides live stock exchange data for Anbio Biotechnology (NASDAQ: NNNN), including its current stock price, symbol, trading exchange, and various financial metrics. It also features a "Scorecard" detailing the company's health, fair value, technical analysis, and re

Tone
Neutral 50/100
Event
Market update
Published
04 Feb 2026 17:59
Source
Investing.com
TipRanks Direct company coverage

Anbio Biotechnology Class A Shares Surge After Volatility Pause

Anbio Biotechnology Class A shares surged following a volatility pause, indicating significant market interest. This rise coincided with the appointment of Michael Zhang as chair of the audit committee, a move designed to enhance governance, investor confidence, and financial tra

Tone
Positive 75/100
Event
Market update
Published
02 Feb 2026 19:28
Source
TipRanks
www.marketscreener.com Direct company coverage

Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026

Anbio Biotechnology announced board and committee changes effective January 21, 2026. Michael Zhang has been appointed as a director, the Chair of the Audit Committee, and a member of both the Nominating and Compensation Committees, replacing Kenneth Li. Kenneth Li's departure wa

Tone
Neutral 50/100
Event
Market update
Published
26 Jan 2026 18:29
Source
www.marketscreener.com
TipRanks Direct company coverage

Anbio Biotechnology Strengthens Board Oversight With Appointment of Michael Zhang as Audit Committee Chair

Anbio Biotechnology has appointed Michael Zhang as director, audit committee chair, and committee member, effective January 21, 2026. Zhang is recognized as an independent audit committee financial expert under U.S. and Nasdaq rules, and his appointment is expected to enhance the

Tone
Positive 69/100
Event
Market update
Published
26 Jan 2026 11:58
Source
TipRanks
The Globe and Mail Direct company coverage

Anbio Biotechnology Posts Higher Margins and Profits Despite Revenue Dip in First Half of 2025

Anbio Biotechnology (NNNN) reported financial results for the first half of 2025, showing a revenue decrease to $4.6 million from $5.8 million, but a significant rise in gross profit to $4.2 million, with margins expanding to 92.3%. Net income also increased to $3.8 million, demo

Tone
Positive 71/100
Event
Earnings
Published
01 Jan 2026 03:09
Source
The Globe and Mail
富途资讯 Direct company coverage

Year-End Review | The 2025 US IPO Gainers List is Out! Anbio Biotechnology Soars Over 570%, 'First Stablecoin Stock' Circle Surges More Than 180%

The 2025 U.S. IPO market saw a significant recovery, driven by a stabilizing macroeconomic environment and renewed investor confidence, with 202 IPOs raising $44 billion. Technology and healthcare companies dominated the top performers, highlighting 'polarization' and 'sector foc

Tone
Neutral 50/100
Event
Market update
Published
27 Dec 2025 06:58
Source
富途资讯
Stock Titan Direct company coverage

NNNN SEC Filings - ANBIO BIOTECHNOLOGY 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for ANBIO BIOTECHNOLOGY (NNNN) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms. It details recent filings such as initial Form 3 reports from directors and executives, and significant corporate actions like cha

Tone
Negative 33/100
Event
Market update
Published
14 Nov 2025 00:39
Source
Stock Titan